RxDoctor Payments Data

Antonio Daria, DO

Internal Medicine · Branford, CTNPI 1447443676

Payments from drug & device makers

$1,380in general payments, 2019–2025

Across 84 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$284
  • AstraZeneca$149
  • Boehringer Ingelheim$147
  • Lilly USA, LLC$132
  • GSK$129
  • Merck$75
  • plus $464 from 16 others

What the payments were for

  • Food & beverage$1,374100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,380 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$80,362
Medicare patients
108
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$89,705
JanuviaSitagliptin Phosphate41$58,278
JardianceEmpagliflozin33$32,916
Repatha SureclickEvolocumab16$18,489
OxycontinOxycodone Hcl26$14,171
Rosuvastatin Calcium368$4,505
Lidocaine12$3,368
Levothyroxine Sodium158$2,034
Amlodipine Besylate186$1,886
Olmesartan Medoxomil95$1,625
Nebivolol Hcl26$1,534
Atorvastatin Calcium172$1,224
Oxycodone Hcl67$1,215
Vilazodone Hcl12$1,210
Duloxetine Hcl16$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$72$89,70568 claims
MerckJanuvia$75$58,27841 claims
Boehringer IngelheimJardiance$147$32,91633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Branford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →